07:02 EDT Supernus (SUPN) to acquire Sage Therapeutics (SAGE) for $8.50 per share in cash plus CVR
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SUPN:
- Supernus expands partnership with Jay Glazer in new content series
- Supernus Pharmaceuticals Faces Patent Challenges for Qelbree
- Supernus announces Paragraph IV ANDA filings for Qelbree
- Supernus partners with Busy Philipps for new campaign
- Supernus Pharmaceuticals’ Earnings Call: Growth Amid Challenges